Ocrevus shows higher efficacy than Rebif on NEDA in RRMS patients, a recent analysis shows

As per a recent analysis published in SAGE journals, based on OPERA I and OPERA II clinical studies, Ocrevus was found to have shown better efficacy than Rebif (interferon beta-1a) on the NEDA parameters in RRMS patients. No evidence of disease activity (NEDA; defined as no 12-week confirmed disability progression, no protocol-defined relapses, no new/enlarging T2 lesions and no T1 gadolinium-enhancing lesions) using a fixed-study entry baseline is commonly used as a treatment outcome in multiple sclerosis (MS).

The objective of this paper was to assess the effect of ocrelizumab on NEDA using re-baselining analysis, and the predictive value of NEDA status.

NEDA was assessed in a modified intent-to-treat population (n = 1520) from the pooled OPERA I and OPERA II studies over various epochs in patients with relapsing MS receiving ocrelizumab (600 mg) or interferon beta-1a (IFN β‐1a; 44 μg).

Results of the analysis:

In the patients on ocrelizumab vs IFN β-1a NEDA was increased, over 96 weeks, by 75% (p < 0.001), from Week 0‒24 by 33% (p < 0.001) and from Week 24‒96 by 72% (p < 0.001). Among patients with disease activity during Weeks 0‒24, 66.4% vs 24.3% achieved NEDA during Weeks 24‒96 in the ocrelizumab and IFN β-1a groups (relative increase: 177%; p < 0.001).

The results clearly demonstrated superior efficacy with ocrelizumab compared with IFN β-1a in maintaining NEDA status in all epochs evaluated.

About Pharmascroll:

Pharmascroll is a diligent business consulting and market research firm focused solely towards pharmaceutical markets. The company consults and researches in majorly chronic disease indications prevalent across the globe. The research conducted by Pharmascroll analysts is targeted to provide analytical and logical answers to the key business questions of the pharmaceutical and medical insights teams and to make better informed business decisions with the detailed relevant information available.

To read more news about Multiple Sclerosis, visit https://pharmascroll.com/news-category/multiple-sclerosis/

News Source: http://journals.sagepub.com/doi/abs/10.1177/2055217318760642

Image Source: https://www.neurologyadvisor.com/aan-2016-coverage/benefit-of-ocrelizumab-seen-in-ms/article/491125/